← Leaderboards
Laurence Reilly
Cellectar Biosciences, Inc.
$1,615,704
Attributed
$3,231,407
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2022–23$2M$1.5M$1M$500K$0
'22
'23
Funding mix
By agency
NIH$3,231,407 · 2
By mechanism
R44$3,231,407 · 2
Top collaborators
- Jarrod Longcor4 shared
Most similar at Cellectar Biosciences, Inc.
Same institution · by research overlap
- Jarrod Longcor$1,997,244
- John Friend$381,540
Others in their field
Other Rising Stars on “Membrane Microdomains”
- Tessa Barrett · New York University School Of Medicine$1,763,213
- Aaron Robert Goldman · University Of Pennsylvania$1,293,622
- Sargis Sedrakyan · Children'S Hospital Of Los Angeles$732,331
- Soo-Ho Choi · University Of California, San Diego$663,714
- Keunyoung Kim · University Of California, San Diego$663,714
- Adem Yildirim · Oregon Health & Science University$662,913
Research focus
Membrane MicrodomainsPharmaceutical PreparationsHalf-LifeMedicalNormal CellOpen LabelDoseFda ApprovedI131 IsotopeMalignant NeoplasmsCell SurvivalNeoplastic CellNormal Tissue MorphologyNovel TherapeuticsClinical DevelopmentClinical TrialsEfficacy EvaluationExposure ToCancer CellAnalogCancer TypeIntravenous AdministrationCell ProliferationPhospholipid Ethers
Grant awards (4)
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$965,201
R44 · FY2023 · CA · contact PI
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$475,806
R44 · FY2023 · CA
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$1,034,797
R44 · FY2022 · CA · contact PI
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$755,603
R44 · FY2022 · CA